AVITA Medical Inc
AVH: XASX (AUS)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
A$4.50 | Mpy | Ybpjstd |
Avita Medical: Regulatory Approval Received for Improved Device as We Expected
As expected, no-moat Avita Medical received regulatory approval for an updated version of its current RECELL device that simplifies the user interface. The timing is no surprise, as Avita had flagged that the updated device should launch on May 30, 2024. As such, we make no changes to our earnings estimates, and our AUD 5.40 fair value estimate remains intact.